The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Towa, Sawai Log Two-Digit Growth in Operating Profit, but Industry Sees Divide: Tally
Japan’s two major generic players Towa Pharmaceutical and Sawai Group Holdings both posted double-digit growth in operating profit in FY2024, forecasting rosy performances to continue this fiscal year as well. Meanwhile, the industry is increasingly polarized, with some companies becoming…
To read the full story
Related Article
- Towa, Sawai Log H1 Sales Gains, but Overseas Woes and Litigation Drag on Profit
November 21, 2025
- Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
June 4, 2025
- Towa/Sawai Log Contrasting 1H Results, Generic Makers Gain Slight Tailwind from New LLP Rule
November 19, 2024
- Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
- Sawai, Towa See Double-Digit Growth in H1, but Stick to Full-Year Forecasts amid Uncertainties
November 29, 2023
- Sawai and Towa Profits Tank 50% on Flat Sales in Japan: FY2022 Earnings
May 22, 2023
- Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
November 18, 2022
BUSINESS
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
- Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025
- Meiji Pharma Sets Up Singapore Unit to Bolster ASEAN Push
December 24, 2025
- Santen Releases VKC Eye Drop Verkazia in China
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…